Logout successfull!
To overview page

ReCerf® receives the European CE mark

Our longtime collaborators at MatOrtho Ltd shared the exciting news that their ReCerf® hip resurfacing – made with BIOLOX®delta ceramic-on-ceramic (CoC) – has received the European CE marking.

A hiker with a backpack climbs a rocky mountain trail. The image includes congratulatory text for MatOrtho, highlighting their achievements: FDA Breakthrough Device Designation in the US in 2023, recognition by the Therapeutic Goods Administration in Australia in 2024, and European CE marking in 2025.

ReCerf® was recently recognized by the Therapeutic Goods Administration (TGA) in Australia and granted Breakthrough Device designation by FDA in the United States.

“This is more than a regulatory milestone. It represents two decades of focused effort to improve hip resurfacing through an advanced material,” said Mike Tuke, Founder of MatOrtho.

“That became a possibility with BIOLOX®delta and cooperation with CeramTec which led in stages to ReCerf® - an all-ceramic resurfacing implant that is already delivering excellent results. We're proud to make this more widely available to specialist hip resurfacing surgeons, and patients who want to stay active.”

Thanks to researchers’ and surgeons’ continuing trust in BIOLOX®delta materials, as well as to the meticulous effort that CeramTec’s engineers and production team invest in crafting each component, a transformative metal-free orthopedic solution is now accessible to a broader patient demographic with different needs.

With ReCerf®, BIOLOX®delta is not just keeping pace – it's moving the field of joint replacement Years Ahead.

Congratulations to MatOrtho and all surgeons involved in  reaching this milestone. 

Please check for regulatory approval in your country.